Arcutis Biotherapeutics Inc - Asset Resilience Ratio
Arcutis Biotherapeutics Inc (ARQT) has an Asset Resilience Ratio of 41.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Arcutis Biotherapeutics Inc (ARQT) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Arcutis Biotherapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Arcutis Biotherapeutics Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Arcutis Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ARQT total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $204.43 Million | 41.85% |
| Total Liquid Assets | $204.43 Million | 41.85% |
Asset Resilience Insights
- Very High Liquidity: Arcutis Biotherapeutics Inc maintains exceptional liquid asset reserves at 41.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcutis Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Arcutis Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Arcutis Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.13% | $178.07 Million | $432.97 Million | -3.76pp |
| 2024-12-31 | 44.89% | $156.62 Million | $348.89 Million | -8.85pp |
| 2023-12-31 | 53.74% | $183.46 Million | $341.37 Million | -25.48pp |
| 2022-12-31 | 79.23% | $355.95 Million | $449.27 Million | +8.03pp |
| 2021-12-31 | 71.20% | $290.61 Million | $408.15 Million | -2.34pp |
| 2020-12-31 | 73.54% | $219.36 Million | $298.27 Million | +38.10pp |
| 2019-12-31 | 35.44% | $37.93 Million | $107.01 Million | +12.85pp |
| 2018-12-31 | 22.60% | $11.55 Million | $51.10 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $3.82 Million | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more